Belvedere Trading’s Biogen BIIB Stock Holding History

Belvedere Trading’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$27.7K	–	953
2022 Q4	$27.7K	Buy	+100	New	+$28.2K	﹤0.01%	774

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Belvedere Trading's BIIB Position: Q1 2023 in Review

Belvedere Trading sold out of Biogen (BIIB) in Q1 2023, closing a stake of 1,675 shares — an estimated $464K sold.

Belvedere Trading first reported a position in BIIB in Q4 2014 and held it in 2 quarters. The position peaked at $1.81M in Q4 2014. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

Belvedere Trading reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 1,675 Biogen shares in Q1 2023, an estimated $464K.
Belvedere Trading first reported a position in Biogen in Q4 2014 and held it in 2 quarters.
Belvedere Trading's Biogen position peaked at $1.81M in Q4 2014.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.